By Tom Crosby, RESI Conference Manager, LSN
Angels represent an extremely important pool of capital for a fundraising entrepreneur, especially now that they have begun syndicating and participating in larger financing rounds. To help RESI attendees better understand how to receive an allocation from an angel, LSN has assembled two top panels of accredited investors — one session focused on biotech investments and the other on medical device opportunities.
The Biotech Angel Groups sessions will be moderated by Bill Whitaker, Managing Director, Co-Chair Life Science Section, Golden Seeds, and will hear from:
Brian Frenzel, Member, Band of Angels
Karl Handelsman, Member, Board of Directors, Life Science Angels
Bernie Rudnick, Managing Director, Mid Atlantic Bio Angels
Barbara Nelsen, Member, Sofia Angels
The Medtech Angel Groups sessions will be moderated by Allan May, Managing Director, Life Science Angels, and will hear from:
Karen Drexler, Founder, Astia
Randy Barko, Member, Hub Investment Management Group
Steven Pollitt, Board Member, Sand Hill Angels
Richard Koffler, Board of Directors, Tech Coast Angels
These sessions will help scientist entrepreneurs understand the perspective of the angel. Angels will explain their investment preferences, and those of their respective syndicates (when angels band together). What sectors are most attractive to angels? How does an angel group filter, evaluate and parse the plethora of deals that surface?
Other topics of discussion will include their criteria for management team, stage of technology, and whether there is a preference for regional or global firms. What is the difference in presenting to an angel group versus a traditional one-on-one investor meeting — and how does the vetting process work? If you’re looking for angel capital to move your technology forward, don’t miss this session of expert insight at RESI.
Next Phase Newsletter 
Leave a comment